Financial analysis of Humana

Humana Inc. (HUM.US) - FY2025 Annual Report

Humana's financial position appears to be under considerable strain. While total revenue reached a record $129.7 billion, reflecting consistent top-line expansion, profitability has deteriorated sharply. Net income for FY2025 came in at approximately $1.19 billion, which is less than half of what the company earned just two years earlier and represents a negative compound annual growth rate of around 20% over the past four years. The stock price, at $257.84, sits near a five-year low, which could suggest the market has been pricing in these headwinds.

The most striking feature is the persistent compression of profitability despite growing revenues. The operating margin, which stood above 4% in FY2022, has been halved to just over 2%. Similarly, the net margin has dwindled to under 1%. This divergence between revenue growth of about 10% year-over-year and a slight decline in net income could indicate significant pressure on the company's medical cost ratios. The benefits expense line, which represents the core cost of providing care, appears to be the primary driver, having grown to over $110 billion and outpacing premium revenue growth in a way that has squeezed the spread.